Pharmacokinetics and absolute bioavailability of diltiazem in humans
- 149 Downloads
- 35 Citations
Summary
Six healthy male volunteers received single doses of diltiazem hydrochloride on three occasions separated by at least 10 days. Modes of administration were: 10-minute intravenous infusion of a 20-mg dose; oral administration of 120 mg in solution form; and oral administration of 120 mg as two 60-mg sustained-release tablets. Diltiazem concentrations were measured by electroncapture gas chromatography in multiple plasma samples drawn during the 36 hours after dosage. Following intravenous administration, mean (±S.E.) pharmacokinetic variables were: elimination half-life, 11.2 (±2.1) hours; volume of distribution, 11.1 (±3.0) liters/kg; and total clearance, 11.5 (±0.7) ml/min/kg. Oral diltiazem in solution form was rapidly absorbed, with peak plasma levels attained at 38 (±6) minutes after the dose. Absolute systemic availability averaged 44% (±4%). Oral administration of sustained-release tablets yielded, as predicted, slower absorption, with peak plasma concentrations attained at an average of 165 (±22) minutes after dosage. Thus, oral diltiazem is incompletely bioavailable after oral administration, mainly because of first-pass hepatic extraction.
Key words
Pharmacokinetics Bioavailability DiltiazemPreview
Unable to display preview. Download preview PDF.
References
- 1.Braunwald E (1980) Calcium channel blockers. Am J Cardiol 46:1045–1046Google Scholar
- 2.Zsotér TT (1980) Calcium antagonists. Am Heart J 99:805–810Google Scholar
- 3.Henry PD (1980) Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem. Am J Cardiol 46:1047–1058Google Scholar
- 4.Rosenthal SJ, Ginsburg R, Lamb IH, Baim DS, Schroeder JS (1980) Efficacy of diltiazem for control of symptoms of coronary arterial spasm. Am J Cardiol 46:1027–1032Google Scholar
- 5.Ochs HR, Bodem G, Bales G, Greenblatt DJ, Smith TW (1978) Increased clearance of digoxin in rabbits during repeated administration. J Pharmacol Exper Ther 205:516–524Google Scholar
- 6.Ochs HR, Otten H, Greenblatt DJ, Dengler HJ (1982) Diazepam absorption: Effects of age, sex, and Billroth gastrectomy. Digest Dis Sci 27:225–230Google Scholar
- 7.Ochs HR, Knüchel M (1982) Pharmakokinetik und absolute Bioverfügbarkeit von Diltiazem. Z Kardiol 71:112Google Scholar
- 8.Ochs HR and Kölle EU (1983) Absolute Bioavailability of Diltiazem. In: A. Fleckenstein et al. (ed) New Calcium Antagonists, Recent Developments and Prospects (Diltiazem Workshop, May 1982), pp 225–228Google Scholar
- 9.Kölle EU, Ochs HR and Vollmer KO (1983) Pharmacokinetic Model of Diltiazem. Arzneim Forsch/Drug Res 33 (11) 7:972–977Google Scholar
- 10.Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–390Google Scholar
- 11.Morselli P, Rovei V, Mitchard M, Durand A, Gomeni R, Larribaud J (1979) Pharmacokinetics and metabolism of diltiazem in man (observations on healthy volunteers and angina pectoris patients). In: Bing RF (ed) Diltiazem Hakone Symposium '78 Amsterdam-Princeton: Excerpta Medica 152–168Google Scholar
- 12.Bighley L, Dimmitt D, McGraw BF (1980) Bioavailability of Diltiazem. Clin Res 28:No. 2Google Scholar
- 13.Piepho R, Bloedow D, Lacz J, Simons M, Runser D, Dimmitt D, Browne R (1981) Pharmacokinetics of Diltiazem. In: Bender F, Greeff K ed. Calciumantagonisten zur Behandlung der Angina pectoris, Hypertonie und Arrhythmie (1. Dilzem Symposium 1981) Amsterdam-Oxford-Princeton: Excerpta Medica, pp 59–65Google Scholar
- 14.Hermann PH, Rodger SD, Remones G, Thenot JP, London DR and Morselli PL (1983) Pharmacokinetics of Diltiazem After Intravenous and Oral Administration. Eur J Clin Pharmacol 24:349–352Google Scholar
- 15.Schomerus M, Spiegelhalter B, Stieren B, Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10:605–612Google Scholar
- 16.Foster TS, Hamann SR, Richards MS, VR, Bryant PJ, Graves DA and McAllister RG (1983) Nifedipine Kinetics and Bioavailability After Single Intravenous and Oral Doses in Normal Subjects. J Clin Pharmacol 23:161–170Google Scholar